UBC Executive and Leadership Team

Bekki Brown, the President & Chief Executive Officer at UBC, directs the overarching strategy and operational execution for the organization. This leadership role involves guiding UBC's mission to make specialty therapies safer and more accessible by partnering with biopharmaceutical companies. Brown oversees the generation of real-world evidence, a critical component of demonstrating product effectiveness, safety, and value, particularly for rare diseases and novel indications. The Chief Executive Officer ensures that UBC's consultative approach, built on decades of epidemiological and operational experience, consistently delivers tailored solutions that support product progression from early-stage research through post-launch patient support services and commercialization. By focusing on enhancing patient care throughout the product lifecycle, Bekki Brown drives the company's impact on healthcare decisions and market access for vital treatments.

Steve Bell, the Chief Financial Officer & Acco Principal at UBC, manages the company's financial health and accounting operations. This executive function is crucial for ensuring the financial stability and strategic resource allocation necessary to support UBC's partnerships with biopharmaceutical companies. Bell oversees all financial planning, budgeting, and reporting activities, providing critical insights that inform executive decision-making regarding product development and commercialization strategies. The Chief Financial Officer & Acco Principal ensures compliance with financial regulations and drives efficiency across all fiscal operations, directly contributing to UBC's ability to generate real-world evidence and enhance patient access to specialty therapies. By maintaining rigorous financial oversight, Steve Bell supports the company's mission to improve healthcare decisions and patient care throughout the entire product lifecycle.

Dean Reiman, the President at UBC, drives operational excellence and strategic initiatives across key business units. This leadership position focuses on executing the company's core mission of partnering with biopharmaceutical companies to improve the safety and accessibility of specialty therapies. Reiman oversees the implementation of evidence-based research methodologies, ensuring the accurate generation of real-world evidence on product effectiveness and value, especially for rare diseases and novel indications. The President ensures that UBC's consultative approach, grounded in extensive epidemiological and operational experience, consistently provides tailored solutions that advance products through clinical development and commercialization phases. By focusing on enhancing patient care and supporting healthcare decisions, Dean Reiman directly contributes to UBC's impact on the entire product lifecycle.

Michael Haratz, the Senior Vice President, Chief Legal Officer at UBC, provides essential legal counsel and oversees all legal affairs for the organization. This critical role ensures that UBC operates in full compliance with all relevant laws and regulations, safeguarding the company's interests as it partners with biopharmaceutical firms. Haratz directs the legal strategy related to evidence generation, product safety, and patient support services, ensuring that all activities align with the company's mission to make therapies safer and more accessible. The Chief Legal Officer plays a key part in structuring agreements and managing risk, particularly concerning novel indications and specialty therapies. By providing expert legal guidance, Michael Haratz supports UBC's commitment to enhancing patient care and facilitating informed healthcare decisions throughout the product lifecycle.